XML 54 R31.htm IDEA: XBRL DOCUMENT v3.25.0.1
Employee Benefit Plans and Stockholders' Equity (Tables)
 12 Months Ended
Dec. 31, 2024
Share-Based Payment Arrangement [Abstract]  
Schedule of Treasury Share Activity Table Text Block
The following table summarizes our treasury share activity for the periods shown:
Twelve Months Ended
December 31,
(In millions)202420232022
Shares issued in connection with 2023 Notes conversions——(0.4)
Shares received from Note Hedge—12.20.3
Shares issued in connection with the Restated Collaboration Agreement(1.5)(3.7)(2.9)
Shares repurchased under the 2022 Share Repurchase Program——6.6
Shares repurchased under the 2023 Share Repurchase Program—4.7—
Shares repurchased under the 2024 Share Repurchase Program10.4——
Shares repurchased with 2028 Notes proceeds—1.6—
Shares issued in connection with 2023 Warrants(12.5)——
Schedule of RSU and PSU Activity
A summary of RSU and PSU activity under the 2015 Plan for the twelve months ended December 31, 2024, 2023 and 2022 is as follows:
Nonvested RSU and PSU Activity
(In millions, except weighted average grant date fair value)Shares Available for GrantSharesWeighted 
Average
Grant Date
Fair Value		Aggregate
Intrinsic Value
Balance at December 31, 202116.8 3.0 $76.88 
Granted(1.9)1.9 96.79 
Vested— (1.6)63.90 
Forfeited0.4 (0.4)92.54 
Balance at December 31, 202215.3 2.9 94.08 $325.6 
Granted(1.6)1.6 112.01 
Vested— (1.4)88.57 
Forfeited0.2 (0.2)106.34 
Balance at December 31, 202313.9 2.9 105.98 361.2 
Granted(1.7)1.7 131.17 
Vested— (1.3)102.09 
Forfeited0.3 (0.3)115.59 
Balance at December 31, 202412.5 3.0 $121.17 $234.1 
Schedule of Share-Based Compensation Expenses The following table summarizes our share-based compensation expense included in our consolidated statements of operations for the periods shown:
Twelve Months Ended
December 31,
(In millions)202420232022
Cost of sales$14.4 $14.6 $11.1 
Research and development52.2 45.5 42.7 
Selling, general and administrative103.8 90.7 72.7 
Total share-based compensation expense$170.4 $150.8 $126.5 
Total tax benefit related to share-based compensation expense$43.8 $40.0 $43.2 
Schedule of Valuation Assumptions for Employee Stock Purchase Plan We estimate the fair value of ESPP purchase rights on the date of grant using the Black-Scholes option pricing model and the assumptions below for the specified reporting periods.
Twelve Months Ended
December 31,
202420232022
Risk free interest rate
4.80% - 5.27%
5.20% - 5.47%
0.60% - 3.34%
Dividend yield— %— %— %
Expected volatility of Dexcom common stock
42% - 85%
34% - 48%
45% - 55%
Expected life (in years)0.50.50.5